Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:fragrance
|
| gptkbp:bfsLayer |
7
|
| gptkbp:bfsParent |
gptkb:Clexane
|
| gptkbp:activities |
inhibits factor I Ia (thrombin)
inhibits factor Xa |
| gptkbp:appointed_by |
subcutaneous injection
|
| gptkbp:approves |
gptkb:1993
gptkb:FDA |
| gptkbp:associated_with |
improved patient outcomes
lower risk of thromboembolism |
| gptkbp:brand |
Lovenox
|
| gptkbp:clinical_trial |
studied for COVID-19 patients
studied for abdominal surgery studied for cancer patients studied for orthopedic surgery |
| gptkbp:contraindication |
active bleeding
severe renal impairment spinal anesthesia epidural anesthesia hypersensitivity to heparin |
| gptkbp:developed_by |
gptkb:Sanofi
|
| gptkbp:formulation |
vials
pre-filled syringes |
| https://www.w3.org/2000/01/rdf-schema#label |
enoxaparin
|
| gptkbp:ingredients |
C21 H28 N2 O37 S
|
| gptkbp:interacts_with |
antiplatelet agents
thrombolytics NSAI Ds |
| gptkbp:is_available_in |
liquid form
injectable form |
| gptkbp:is_available_on |
generic version
brand name version |
| gptkbp:is_monitored_by |
anti-Xa levels
platelet counts |
| gptkbp:is_used_for |
preventing blood clots
treating pulmonary embolism preventing deep vein thrombosis |
| gptkbp:manager |
subcutaneous
|
| gptkbp:marketed_as |
many countries
|
| gptkbp:pharmacokinetics |
antithrombotic effect
bioavailability 90% or more half-life 4.5 hours |
| gptkbp:related_to |
gptkb:heparin
low molecular weight heparin |
| gptkbp:side_effect |
bleeding
pain at injection site thrombocytopenia |
| gptkbp:storage |
room temperature
|
| gptkbp:suitable_for |
gptkb:municipality
|
| gptkbp:traded_on |
gptkb:Clexane
Klexane |
| gptkbp:type_of |
9004-54-0
|
| gptkbp:used_in |
hospital settings
outpatient settings |